Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial

Faster, Cleaner, Better.

Dare Bioscience Inc (DARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Cash Flow for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)

	12-2015	12-2014	12-2013	12-2012	12-2006
Cash Flows From Operating Activities
Net Income	-39,594	-23,342	-17,143	-22,101	N/A
Depreciation Amortization	931	341	412	346	N/A
Accounts receivable	342	-695	-209	-61	N/A
Accounts payable and accrued liabilities	795	341	14	-163	N/A
Other Working Capital	4,420	1,065	-309	265	N/A
Other Operating Activity	1,191	3,229	621	709	0
Operating Cash Flow	$-31,915	$-19,061	$-16,614	$-21,005	$N/A

Cash Flows From Investing Activities
PPE Investments	-254	-185	-7	-180	N/A
Other Investing Activity	-230	0	0	0	0
Investing Cash Flow	$-484	$-185	$-7	$-180	$N/A

Cash Flows From Financing Activities
Change In Short Term Borrowing	N/A	8,500	8,824	N/A	N/A
Debt Issued	21,000	N/A	N/A	10,000	N/A
Debt Repayment	-3,321	-3,348	-3,084	-379	N/A
Common Stock Issued	39,813	60,002	35	3	N/A
Other Financing Activity	-359	-222	-373	12,923	0
Financing Cash Flow	$57,133	$64,932	$5,402	$22,547	$N/A

Beginning Cash Position	51,174	5,488	16,707	15,345	N/A
End Cash Position	75,908	51,174	5,488	16,707	N/A
Net Cash Flow	$24,734	$45,686	$-11,219	$1,362	$N/A

Free Cash Flow
Operating Cash Flow	-31,915	-19,061	-16,614	-21,005	N/A
Capital Expenditure	-277	-225	-7	-180	N/A
Free Cash Flow	-32,192	-19,286	-16,621	-21,185	0